Bio-Path HoldingsBPTH
Market Cap: $2.51M
About: Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Employees: 10
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
262% more capital invested
Capital invested by funds: $78.7K [Q1] → $285K (+$206K) [Q2]
30% more funds holding
Funds holding: 10 [Q1] → 13 (+3) [Q2]
4.05% more ownership
Funds ownership: 2.81% [Q1] → 6.86% (+4.05%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Roth MKM Philip Shen 29% 1-year accuracy 7 / 24 met price target | 1,933%upside $20 | Buy Reiterated | 8 Jul 2024 |
Financial journalist opinion
Based on 4 articles about BPTH published over the past 30 days